News
EIGR
6.24
+2.30%
0.14
AbbVie taps priority review voucher to expand Rinvoq into ulcerative colitis
AbbVie has used a priority review voucher to expand the indication of Rinvoq (upadacitinib) to include moderately to severely active ulcerative colitis. The approval was noted in a Federal Register posting
Seekingalpha · 2d ago
BRIEF-Eiger BioPharmaceuticals Announces New Data Supporting Broader Potential Of Avexitide In Patients With Post-Bariatric Hypoglycemia And Hyperinsulinemic Hypoglycemia After Gastrointestinal Surgeries
reuters.com · 06/13 12:16
Eiger BioPharmaceuticals Announces New Data Supporting Broader Potential of Avexitide in Patients with Post-Bariatric Hypoglycemia and Hyperinsulinemic Hypoglycemia After Gastrointestinal Surgeries
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced Phase 2b results of ave...
PR Newswire · 06/13 12:00
The Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 06/08 13:07
Eiger Biopharmaceuticals Announces Multiple Presentations At The European Association For The Study Of The Liver (EASL) International Liver Congress 2022
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases,
Benzinga · 06/08 12:11
Eiger BioPharmaceuticals Announces Multiple Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced four abstracts to be pr...
PR Newswire · 06/08 12:00
BRIEF-Eiger Biopharmaceuticals Enters Into $75M Term Loan Agreement And $5M Stock Purchase Agreement With Innovatus Capital Partners To Refinance Existing Debt Facility And Further Strengthen Cash Position Ahead Of Key Milestones
reuters.com · 06/07 20:28
Eiger BioPharmaceuticals enter $75M term loan and $5M stock repurchase agreement to bolster cash position
Commercial-stage biopharmaceutical company focused on innovative therapies to treat and cure hepatitis delta virus, Eiger BioPharmaceuticals (NASDAQ:EIGR -0.6%) entered into a term loan agreement with an affiliate of Innovatus Capital Partners
Seekingalpha · 06/07 20:22
Eiger Biopharmaceuticals Enters Into $75M Term Loan Agreement And $5M Stock Purchase Agreement
Eiger BioPharmaceuticals Enters into $75M Term Loan Agreement and $5M Stock Purchase Agreement with Innovatus Capital Partners to Refinance Existing Debt Facility and Further Strengthen Cash Position Ahead of Key
Benzinga · 06/07 20:14
Eiger BioPharmaceuticals Signs $75 Million Term Loan Deal, $5 Million Stock Purchase Agreement With Innovatus
MT Newswires · 06/07 16:25
Eiger BioPharmaceuticals to Present at the Jefferies Global Healthcare Conference
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced that David Cory, Presid...
PR Newswire · 06/03 12:00
EMA's Advisory Committee Recommends Eiger's Zokinvy In Premature Aging Disorder
Benzinga · 05/20 19:14
EU drug regulator panel recommends approval for Eiger BioPharma's progeria therapy
Eiger BioPharmaceuticals (NASDAQ:EIGR) on Friday said that a European Union drug regulator committee had recommended approval of the company's therapy Zokinvy as the first treatment in the region for premature
Seekingalpha · 05/20 13:21
BRIEF-Eiger Receives Positive CHMP Opinion For Zokinvy As A Treatment For Hutchinson-Gilford Progeria Syndrome And Processing-Deficient Progeroid Laminopathies
reuters.com · 05/20 12:44
Eiger Receives Positive CHMP Opinion for Zokinvy as a Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies
Eiger BioPharmaceuticals Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus and other serious diseases, announced today that the Committee for Medicin...
PR Newswire · 05/20 12:39
Eiger BioPharmaceuticals Receives Positive Opinion for Hutchinson-Gilford Progeria Syndrome Treatment Approval in Europe
MT Newswires · 05/20 09:27
Things Look Grim For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) After Today's Downgrade
The analysts covering Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) delivered a dose of negativity to shareholders...
Simply Wall St. · 05/12 10:25
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/11 13:37
BRIEF-Eiger BioPharmaceuticals And AnGes Enter Partnership For Lonafarnib In Japan
reuters.com · 05/10 21:30
Eiger Biopharmaceuticals And AnGes Announce Exclusive Partnership For Regulatory Approval And Commercialization Of Zokinvy In Japan
Eiger Biopharmaceuticals Inc. ((", Eiger", , NASDAQ:EIGR) and AnGes Inc. ((", AnGes", , TYO:4563) today announced that the companies entered into an agreement for the regulatory approval, marketing,
Benzinga · 05/10 21:23
More
Webull provides a variety of real-time EIGR stock news. You can receive the latest news about Eiger Biopharma through multiple platforms. This information may help you make smarter investment decisions.
About EIGR
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development of therapies to treat and cure Hepatitis Delta Virus (HDV), the severe form of viral hepatitis, and other serious diseases. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV and Covid-19, Avexitide in Post-Bariatric Hypoglycemia (PBH) and Avexitide in Congenital Hyperinsulinism (CHI). Lambda is a late-stage, type III, interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections. Avexitide is a peptide, which is developing as a treatment for congenital hyperinsulinism (HI). It is also developing lambda as an out-patient treatment for patients with mild and moderate COVID-19. The Company is also developing Avexitide as a treatment for post-bariatric hypoglycemia (PBH).